Table 2.
Diagnostic accuracy of Hemochron® Signature POCT for rivaroxaban
| Coagulation test result | Threshold (ng/mL) | Specificity (%) | Sensitivity (%) | LR | PPV (%) | NPV (%) |
|---|---|---|---|---|---|---|
| POCT PT ≤1.0 | <30 | 97 (89–100) | 33 (20–48) | 11.6 | 88 | 69 |
| POCT PT ≤1.1 | <100 | 96 (85–99) | 38 (27–50) | 9.0 | 93 | 52 |
| POCT ACT+ ≤120 s | <30 | 96 (87–99) | 67 (52–80) | 15.7 | 91 | 82 |
| POCT ACT+ ≤130 s | <100 | 96 (85–99) | 68 (55–78) | 16.2 | 96 | 68 |
n = 118 samples
Sensitivity and specificity are provided with 95% confidence intervals
ACT+ activated clotting time plus, LR likelihood ratio, NPV negative predictive value, POCT point of care test, PPV positive predictive value, PT prothrombin time